We are live on ! Find out more
TARA icon

Protara Therapeutics

33 hedge funds and large institutions have $118M invested in Protara Therapeutics in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 4

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

23% more capital inflows, than outflows

Capital inflows: $9.07M | Capital outflows: $7.38M

18% more funds holding

Funds holding: 28 → 33 (+5)

0.11% more ownership

Funds ownership: 67.7% → 67.81% (+0.11%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
33
Holders Change
+5
Holders Change %
+17.86%
% of All Funds
0.67%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
12
Increased
13
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

TARA Hedge Fund Activity: Q2 2020 in Review

33 of the 4,891 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2020, worth a combined $118M — up 27% from $92.3M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new TARA positions and 7 closed out — a net gain of 5 holders — while 13 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $2.84M. The largest seller was DRW Securities, exiting entirely with an estimated $3.07M sold.

  • 33 institutional investors held Protara Therapeutics (TARA) as of Q2 2020, up from 28 in Q1 2020.
  • Funds reported $118M of Protara Therapeutics stock for Q2 2020, up 27% quarter-over-quarter.
  • 12 funds opened new Protara Therapeutics positions in Q2 2020 and 7 closed out, a net change of +5 holders.
  • The largest Protara Therapeutics buyer in Q2 2020 was BlackRock, an estimated $2.84M added.
  • The largest Protara Therapeutics seller in Q2 2020 was DRW Securities, an estimated $3.07M sold.

Based on aggregated 13F filings for Q2 2020.